Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients
This study is currently recruiting patients.
Sponsored by: | FDA Office of Orphan Products Development |
---|---|
Information provided by: | FDA Office of Orphan Products Development |
Purpose
This is a study to determine if oral arginine will increase nitric oxide in sickle cell disease (SCD) patients with acute chest syndrome (ACS). It will also assess the effects of arginine in the body and how the body uses nitric oxide in ACS.
Condition | Treatment or Intervention | Phase |
---|---|---|
Anemia, Sickle Cell Pneumonia |
Drug: Arginine hydrochloride |
Phase II |
MedlinePlus related topics: Pneumonia; Sickle Cell Anemia
Genetics Home Reference related topics: sickle cell anemia
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Uncontrolled, Parallel Assignment, Efficacy Study
Official Title: Arginine Therapy for Acute Chest Syndrome in Sickle Cell Disease
Expected Total Enrollment: 30
Study start: August 2001;
Study completion: July 2004
Pneumonia in patients with SCD can be particularly severe and has come to be called acute chest syndrome. ACS is a common cause of morbidity in SCD patients and is the most common cause of death in SCD. Multiple factors are involved in the severity of acute pulmonary injury in SCD. Nitric oxide has a multitude of related functions, many of which could impact favorably on ACS in SCD. Nitric oxide is an important inflammatory mediator which is produced by the conversion of L-arginine to citrulline by nitric oxide synthase. Nitric oxide and its precursor, arginine, are known to be low in SCD patients with ACS, suggesting that therapies, such as arginine, aimed at increasing nitric oxide production will improve the clinical course of ACS. Patients will receive 1 of 3 doses of arginine hydrochloride orally 3 times a day for 3 days while hospitalized. The efficacy of arginine will be measured by the increase in nitric oxide production and the physiological effects will be assessed.
Eligibility
Ages Eligible for Study: 5 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion criteria:
Acute chest syndrome with the following:
Exclusion criteria:
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |